QUICK ANSWER · AEO / GEO
Ramatercept is an ActRIIB-IgG1 Fc ligand trap, not follistatin. Short human trials found body-composition signals but did not establish functional benefit; the DMD Phase 2 study stopped on safety concerns including epistaxis and telangiectasias. Unverified online products cannot inherit clinical-trial evidence.
ENTITY FACTS
What should readers identify first?
What remains unknown?
Insufficient data in the current dataset
What limits these conclusions?
Insufficient data in the current dataset
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://pubmed.ncbi.nlm.nih.gov/23169607/
- https://pubmed.ncbi.nlm.nih.gov/27462804/
- https://clinicaltrials.gov/study/NCT01099761
- https://pubmed.ncbi.nlm.nih.gov/40312924/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12489275/
- https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- https://www.boe.es/eli/es/res/2025/12/02/%282%29
FAQ · ANSWER ENGINE
Frequently asked questions
What is ACE-031?
ACE-031 is described pharmacologically as Soluble activin receptor type IIB–IgG1 Fc fusion protein and broad ligand trap. Ramatercept is an ActRIIB-IgG1 Fc ligand trap, not follistatin. Short human trials found body-composition signals but did not establish functional benefit; the DMD Phase 2 study stopped on safety concerns including epistaxis and telangiectasias. Unverified online products cannot inherit clinical-trial evidence.
Does ACE-031 have strong evidence?
PrimeCoreBio records Evidence Grade B. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is ACE-031 approved everywhere?
No global conclusion should be inferred. PrimeCore Class B must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.